CA3238160A1 - Dickkopf-1 variant antibodies and methods of use - Google Patents
Dickkopf-1 variant antibodies and methods of use Download PDFInfo
- Publication number
- CA3238160A1 CA3238160A1 CA3238160A CA3238160A CA3238160A1 CA 3238160 A1 CA3238160 A1 CA 3238160A1 CA 3238160 A CA3238160 A CA 3238160A CA 3238160 A CA3238160 A CA 3238160A CA 3238160 A1 CA3238160 A1 CA 3238160A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- fragment
- instances
- seq
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163280840P | 2021-11-18 | 2021-11-18 | |
| US63/280,840 | 2021-11-18 | ||
| US202163286522P | 2021-12-06 | 2021-12-06 | |
| US63/286,522 | 2021-12-06 | ||
| US202263374497P | 2022-09-02 | 2022-09-02 | |
| US63/374,497 | 2022-09-02 | ||
| US202263379634P | 2022-10-14 | 2022-10-14 | |
| US63/379,634 | 2022-10-14 | ||
| PCT/US2022/050322 WO2023091614A2 (en) | 2021-11-18 | 2022-11-17 | Dickkopf-1 variant antibodies and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3238160A1 true CA3238160A1 (en) | 2023-05-25 |
Family
ID=86397718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3238160A Pending CA3238160A1 (en) | 2021-11-18 | 2022-11-17 | Dickkopf-1 variant antibodies and methods of use |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12134656B2 (https=) |
| EP (1) | EP4433085A2 (https=) |
| JP (1) | JP2024542194A (https=) |
| KR (1) | KR20240101677A9 (https=) |
| AU (1) | AU2022390457A1 (https=) |
| CA (1) | CA3238160A1 (https=) |
| IL (1) | IL312714A (https=) |
| WO (1) | WO2023091614A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113766930B (zh) | 2019-02-26 | 2025-07-22 | 特韦斯特生物科学公司 | Glp1受体的变异核酸文库 |
| JP2022548783A (ja) | 2019-09-23 | 2022-11-21 | ツイスト バイオサイエンス コーポレーション | 単一ドメイン抗体のバリアント核酸ライブラリー |
| EP4034566A4 (en) | 2019-09-23 | 2024-01-24 | Twist Bioscience Corporation | VARIANT NUCLEIC ACID BANKS FOR CRTH2 |
| BR112022011235A2 (pt) | 2019-12-09 | 2022-12-13 | Twist Bioscience Corp | Bibliotecas de variantes de ácido nucleico para receptores de adenosina |
| EP4204460A4 (en) | 2020-08-26 | 2024-09-25 | Twist Bioscience Corporation | METHODS AND COMPOSITIONS RELATING TO GLP1R VARIANTS |
| KR20230147617A (ko) | 2021-01-21 | 2023-10-23 | 트위스트 바이오사이언스 코포레이션 | 아데노신 수용체에 관한 방법 및 조성물 |
| EP4314075A4 (en) | 2021-03-24 | 2025-04-09 | Twist Bioscience Corporation | VARIANT NUCLEIC ACID BANKS FOR CD3 |
| US12134656B2 (en) | 2021-11-18 | 2024-11-05 | Twist Bioscience Corporation | Dickkopf-1 variant antibodies and methods of use |
| EP4695287A1 (en) | 2023-04-14 | 2026-02-18 | Twist Bioscience Corporation | Compositions and methods related to dkk1 binders |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| EP2140261A4 (en) | 2007-03-26 | 2010-06-16 | Genizon Biosciences Inc | METHODS AND AGENTS FOR ASSESSING INFLAMMATORY ABDOMINAL INFECTION AND TARGETS FOR TREATMENT |
| US20130090457A1 (en) | 2008-10-31 | 2013-04-11 | Janssen Biotech, Inc. | Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases |
| WO2010130832A2 (en) * | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions |
| EP4012714A1 (en) * | 2010-03-23 | 2022-06-15 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| CN104109207B (zh) | 2013-04-17 | 2017-12-12 | 上海市肺科医院 | 肺靶向性抗肺泡表面活性蛋白a的纳米抗体及其制备方法 |
| US20160297883A1 (en) | 2013-12-04 | 2016-10-13 | Innovative Targeting Solutions, Inc. | G-protein coupled receptor agonists and methods |
| WO2016022557A1 (en) | 2014-08-05 | 2016-02-11 | Twist Bioscience Corporation | Cell free cloning of nucleic acids |
| CA2975855C (en) | 2015-02-04 | 2025-09-23 | Twist Bioscience Corporation | SYNTHETIC GENE COMPOSITIONS AND ASSEMBLY METHODS |
| US10669304B2 (en) | 2015-02-04 | 2020-06-02 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
| US9981239B2 (en) | 2015-04-21 | 2018-05-29 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
| US20160333340A1 (en) | 2015-05-11 | 2016-11-17 | Twist Bioscience Corporation | Compositions and methods for nucleic acid amplification |
| EP3350314A4 (en) | 2015-09-18 | 2019-02-06 | Twist Bioscience Corporation | OLIGONUCLEIC ACID VARIANT LIBRARIES VARIANT AND SYNTHESIS THEREOF |
| KR102794025B1 (ko) | 2015-09-22 | 2025-04-09 | 트위스트 바이오사이언스 코포레이션 | 핵산 합성을 위한 가요성 기판 |
| CN115920796A (zh) | 2015-12-01 | 2023-04-07 | 特韦斯特生物科学公司 | 功能化表面及其制备 |
| CA3027127A1 (en) | 2016-06-10 | 2017-12-14 | Twist Bioscience Corporation | Systems and methods for automated annotation and screening of biological sequences |
| CN110088281A (zh) | 2016-08-03 | 2019-08-02 | 特韦斯特生物科学公司 | 用于多核苷酸合成的纹理化表面 |
| EP3500672A4 (en) | 2016-08-22 | 2020-05-20 | Twist Bioscience Corporation | DE NOVO SYNTHETIZED NUCLEIC ACID LIBRARIES |
| US10417457B2 (en) | 2016-09-21 | 2019-09-17 | Twist Bioscience Corporation | Nucleic acid based data storage |
| IL266681B2 (en) | 2016-11-18 | 2025-01-01 | Twist Bioscience Corp | Polynucleotide libraries with controlled stoichiometry and their synthesis |
| GB2573069A (en) | 2016-12-16 | 2019-10-23 | Twist Bioscience Corp | Variant libraries of the immunological synapse and synthesis thereof |
| EP4556433A3 (en) | 2017-02-22 | 2025-08-06 | Twist Bioscience Corporation | Nucleic acid based data storage |
| WO2018170169A1 (en) | 2017-03-15 | 2018-09-20 | Twist Bioscience Corporation | Variant libraries of the immunological synapse and synthesis thereof |
| AU2018234624B2 (en) | 2017-03-15 | 2023-11-16 | Twist Bioscience Corporation | De novo synthesized combinatorial nucleic acid libraries |
| WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| WO2018231872A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| US11407837B2 (en) | 2017-09-11 | 2022-08-09 | Twist Bioscience Corporation | GPCR binding proteins and synthesis thereof |
| CN111565834B (zh) | 2017-10-20 | 2022-08-26 | 特韦斯特生物科学公司 | 用于多核苷酸合成的加热的纳米孔 |
| EP3701023A4 (en) | 2017-10-27 | 2021-07-28 | Twist Bioscience Corporation | POLYNUCLEOTIDE CLASSIFICATION SYSTEMS AND METHODS |
| KR102804057B1 (ko) | 2018-01-04 | 2025-05-07 | 트위스트 바이오사이언스 코포레이션 | Dna 기반 디지털 정보 저장 |
| CA3100739A1 (en) | 2018-05-18 | 2019-11-21 | Twist Bioscience Corporation | Polynucleotides, reagents, and methods for nucleic acid hybridization |
| WO2020139871A1 (en) | 2018-12-26 | 2020-07-02 | Twist Bioscience Corporation | Highly accurate de novo polynucleotide synthesis |
| CA3131514A1 (en) | 2019-02-25 | 2020-09-03 | Twist Bioscience Corporation | Compositions and methods for next generation sequencing |
| JP2022522668A (ja) | 2019-02-26 | 2022-04-20 | ツイスト バイオサイエンス コーポレーション | 抗体を最適化するための変異体核酸ライブラリ |
| CN113766930B (zh) | 2019-02-26 | 2025-07-22 | 特韦斯特生物科学公司 | Glp1受体的变异核酸文库 |
| US11332738B2 (en) | 2019-06-21 | 2022-05-17 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
| JP2022548783A (ja) | 2019-09-23 | 2022-11-21 | ツイスト バイオサイエンス コーポレーション | 単一ドメイン抗体のバリアント核酸ライブラリー |
| EP4034566A4 (en) | 2019-09-23 | 2024-01-24 | Twist Bioscience Corporation | VARIANT NUCLEIC ACID BANKS FOR CRTH2 |
| BR112022011235A2 (pt) | 2019-12-09 | 2022-12-13 | Twist Bioscience Corp | Bibliotecas de variantes de ácido nucleico para receptores de adenosina |
| MX2022013499A (es) | 2020-04-27 | 2023-01-16 | Twist Bioscience Corp | Bibliotecas de ácidos nucleicos variantes para coronavirus. |
| CA3184821A1 (en) | 2020-07-07 | 2022-01-13 | Jeremy Lackey | Devices and methods for light-directed polymer synthesis |
| WO2022046797A1 (en) | 2020-08-25 | 2022-03-03 | Twist Bioscience Corporation | Compositions and methods for library sequencing |
| EP4204460A4 (en) | 2020-08-26 | 2024-09-25 | Twist Bioscience Corporation | METHODS AND COMPOSITIONS RELATING TO GLP1R VARIANTS |
| CN117043171A (zh) | 2020-08-28 | 2023-11-10 | 特韦斯特生物科学公司 | 用于合成的装置和方法 |
| CA3194398A1 (en) | 2020-10-05 | 2022-04-14 | Twist Bioscience Corporation | Hybridization methods and reagents |
| EP4229210A4 (en) | 2020-10-19 | 2025-01-08 | Twist Bioscience Corporation | METHOD FOR THE SYNTHESIS OF OLIGONUCLEOTIDES USING BOUND NUCLEOTIDES |
| US20220206001A1 (en) | 2020-10-22 | 2022-06-30 | Twist Bioscience Corporation | Methods and systems for detecting coronavirus |
| US20220135965A1 (en) | 2020-10-26 | 2022-05-05 | Twist Bioscience Corporation | Libraries for next generation sequencing |
| US20220135690A1 (en) | 2020-11-03 | 2022-05-05 | Twist Bioscience Corporation | Methods and compositions relating to chemokine receptor variants |
| KR20230147617A (ko) | 2021-01-21 | 2023-10-23 | 트위스트 바이오사이언스 코포레이션 | 아데노신 수용체에 관한 방법 및 조성물 |
| US20220277808A1 (en) | 2021-02-19 | 2022-09-01 | Twist Bioscience Corporation | Libraries for identification of genomic variants |
| EP4314075A4 (en) | 2021-03-24 | 2025-04-09 | Twist Bioscience Corporation | VARIANT NUCLEIC ACID BANKS FOR CD3 |
| US20220323924A1 (en) | 2021-03-24 | 2022-10-13 | Twist Bioscience Corporation | Electrochemical polynucleotide synthesis |
| WO2022204309A1 (en) | 2021-03-24 | 2022-09-29 | Twist Bioscience Corporation | Variant nucleic acid libraries for tigit |
| US20220356463A1 (en) | 2021-04-09 | 2022-11-10 | Twist Bioscience Corporation | Libraries for mutational analysis |
| WO2022235584A1 (en) | 2021-05-03 | 2022-11-10 | Twist Bioscience Corporation | Variant nucleic acid libraries for glycans |
| WO2022235579A1 (en) | 2021-05-03 | 2022-11-10 | Twist Bioscience Corporation | Variant nucleic acid libraries for ion channels |
| US12201857B2 (en) | 2021-06-22 | 2025-01-21 | Twist Bioscience Corporation | Methods and compositions relating to covid antibody epitopes |
| WO2023023183A2 (en) | 2021-08-17 | 2023-02-23 | Twist Bioscience Corporation | Sars-cov-2 antibodies and related compositions and methods of use |
| US20230192819A1 (en) | 2021-08-17 | 2023-06-22 | Twist Bioscience Corporation | Single domain antibodies for sars-cov-2 |
| WO2023023285A2 (en) | 2021-08-19 | 2023-02-23 | Twist Bioscience Corporation | Methods and compositions relating to covalently closed nucleic acids |
| JP2024547018A (ja) | 2021-10-18 | 2024-12-26 | ツイスト バイオサイエンス コーポレーション | 連続配列決定に関する方法および組成物 |
| WO2023076419A2 (en) | 2021-10-27 | 2023-05-04 | Twist Bioscience Corporation | Sars-cov-2 antibodies and methods of use |
| EP4466284A2 (en) | 2021-10-27 | 2024-11-27 | Twist Bioscience Corporation | Multispecific sars-cov-2 antibodies and methods of use |
| US20230158469A1 (en) | 2021-11-01 | 2023-05-25 | Twist Bioscience Corporation | Devices and methods for synthesis |
| WO2023091609A2 (en) | 2021-11-18 | 2023-05-25 | Twist Bioscience Corporation | Cytokine variant antibodies and methods of use |
| US12134656B2 (en) | 2021-11-18 | 2024-11-05 | Twist Bioscience Corporation | Dickkopf-1 variant antibodies and methods of use |
| EP4441099A2 (en) | 2021-12-01 | 2024-10-09 | Twist Bioscience Corporation | Neuropilin-1 variant antibodies and methods of use |
| EP4444905A2 (en) | 2021-12-08 | 2024-10-16 | Twist Bioscience Corporation | Nanoelectric devices and use thereof |
| US20230323449A1 (en) | 2021-12-17 | 2023-10-12 | Twist Bioscience Corporation | Compositions and methods for detection of variants |
| EP4460516A2 (en) | 2022-01-03 | 2024-11-13 | Twist Bioscience Corporation | Bispecific sars-cov-2 antibodies and methods of use |
| US20230340461A1 (en) | 2022-02-14 | 2023-10-26 | Twist Bioscience Corporation | Combinatorial dna assembly for multispecific antibodies |
| US20230407290A1 (en) | 2022-03-07 | 2023-12-21 | Twist Bioscience Corporation | Methylation-mediated adapter removal on nucleic acid sequences |
| WO2023192635A2 (en) | 2022-04-01 | 2023-10-05 | Twist Bioscience Corporation | Libraries for methylation analysis |
| WO2023196499A1 (en) | 2022-04-07 | 2023-10-12 | Twist Bioscience Corporation | Substrate cleavage for nucleic acid synthesis |
| CA3249936A1 (en) | 2022-04-21 | 2023-10-26 | Atlas Data Storage, Inc. | Codecs for dna data storage |
-
2022
- 2022-11-17 US US18/056,679 patent/US12134656B2/en active Active
- 2022-11-17 KR KR1020247019566A patent/KR20240101677A9/ko active Pending
- 2022-11-17 EP EP22896498.7A patent/EP4433085A2/en not_active Withdrawn
- 2022-11-17 WO PCT/US2022/050322 patent/WO2023091614A2/en not_active Ceased
- 2022-11-17 IL IL312714A patent/IL312714A/en unknown
- 2022-11-17 AU AU2022390457A patent/AU2022390457A1/en active Pending
- 2022-11-17 JP JP2024529460A patent/JP2024542194A/ja active Pending
- 2022-11-17 CA CA3238160A patent/CA3238160A1/en active Pending
-
2024
- 2024-09-30 US US18/902,114 patent/US20250075004A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024542194A (ja) | 2024-11-13 |
| US12134656B2 (en) | 2024-11-05 |
| EP4433085A2 (en) | 2024-09-25 |
| US20230312749A1 (en) | 2023-10-05 |
| AU2022390457A1 (en) | 2024-06-20 |
| US20250075004A1 (en) | 2025-03-06 |
| IL312714A (en) | 2024-07-01 |
| WO2023091614A3 (en) | 2023-11-02 |
| WO2023091614A2 (en) | 2023-05-25 |
| KR20240101677A (ko) | 2024-07-02 |
| KR20240101677A9 (ko) | 2025-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12202905B2 (en) | Methods and compositions relating to adenosine receptors | |
| US12091777B2 (en) | Variant nucleic acid libraries for CRTH2 | |
| US12565715B2 (en) | Variant nucleic acid libraries for antibody optimization | |
| US20250270737A1 (en) | Antibodies That Bind GLP1R | |
| US12570750B2 (en) | Antibodies that bind adenosine A2A receptors and methods of use thereof to treat cancer and neurological diseases | |
| US12173282B2 (en) | Antibodies that bind CD3 epsilon | |
| US12258406B2 (en) | Antibodies that bind CD3 Epsilon | |
| CA3238160A1 (en) | Dickkopf-1 variant antibodies and methods of use | |
| US20220135690A1 (en) | Methods and compositions relating to chemokine receptor variants | |
| US20230265179A1 (en) | Cytokine variant antibodies and methods of use | |
| US20230265198A1 (en) | Neuropilin-1 variant antibodies and methods of use | |
| HK40080611A (en) | Variant nucleic acid libraries for adenosine receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20241108 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241129 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250807 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251006 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251006 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251107 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251107 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251210 |